PRESS RELEASES

Date	Title
May 23, 2023	Ardelyx, Inc. Reports Employment Inducement Grants
May 17, 2023	Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
May 15, 2023	Ardelyx, Inc. Reports Employment Inducement Grants
May 9, 2023	Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 3, 2023	Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
May 1, 2023	Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
Apr 26, 2023	Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
Apr 18, 2023	Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
Apr 13, 2023	Ardelyx, Inc. Reports Employment Inducement Grants
Apr 12, 2023	Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 617.675.ARDX (2739)

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com